1 Title

2 Estimation of the number of RSV-associated hospitalisations in adults in the European

3 Union

4 Running title: RSV-associated hospitalisation in the EU

- 5 **Authors:** Richard Osei-Yeboah¹, Peter Spreeuwenberg², Marco Del Riccio^{2, 3}, Thea K.
- 6 Fischer^{4,5}, Amanda Cavling^{4,5}, Håkon Boas⁶, Michiel van Boven^{7,8}, Xin Wang⁹, Toni
- 7 Lehtonen¹⁰, Mathieu Bangert¹¹, Harry Campbell¹, John Paget²; on behalf of the RESCEU
- 8 investigators

9 Affiliations:

- 10 1. Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK
- 12 2. Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands
- 12 3. Postgraduate Medical School in Public Health, University of Florence, 50134
- 13 Florence, Italy
- 14 4. Statens Serum Institut, Copenhagen, Denmark
- 15 5. Departments of Clinical Research Nordsjaellands Hospital, Hilleroed and Public
- 16 Health, University of Copenhagen, Denmark
- Department of Infection Control and Vaccines, Norwegian Institute of Public Health,
 Oslo, Norway.
- 197. Centre for Infectious Disease Control, National Institute for Public Health and the
- 20 Environment, Bilthoven, The Netherlands
- Julius Center for Health Sciences and Primary Care, University Medical Center
 Utrecht, Utrecht University, Utrecht, The Netherlands
- 23 9. School of Public Health, Nanjing Medical University, Nanjing, China
- 24 10. Department of Health Security, Finnish Institute for Health and Welfare (THL),
- 25 Helsinki, Finland
- 26 11. Sanofi Vaccines, Lyon, France
- 27 Corresponding author
- 28 Richard Osei-Yeboah, Centre for Global Health, Usher Institute, University of Edinburgh,
- 29 Edinburgh, UK
- 30 Email: <u>Richard.Osei-Yeboah@ed.ac.uk</u>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

32 Background: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract

- 33 infections in older adults that can result in hospitalisations and death. Estimating RSV-
- 34 associated hospitalisation is critical for planning RSV-related healthcare needs for the ageing
- 35 population across Europe.

36 Methods: We gathered national RSV-associated hospitalisation estimates from the

- 37 REspiratory Syncytial virus Consortium in EUrope (RESCEU) for adults in Denmark, England,
- Finland, Norway, Netherlands, and Scotland from 2006 to 2017. We extrapolated these

39 estimates to 28 EU countries using nearest-neighbour matching, multiple imputations, and

40 two sets of 10 indicators.

Results: On average, 158 229 (95%CI: 140 865-175 592) RSV-associated hospitalisations
occur annually among adults in the EU (above 18 years); 92% of these hospitalisations occur
in adults over 65 years. Among 75-84 years old, the annual average is estimated at 74 519
(95%CI: 69 923-79 115) at a rate of 2.24 (95%CI: 2.10-2.38) per 1000 adults. Among adults
aged ≥85 years, the annual average is estimated at 37 904 (95%CI: 32 444-43 363) at a rate
of 2.99 (95%CI: 2.56-3.42).

47 Conclusion: Our estimates of RSV-associated hospitalisations in older adults are the first
48 analysis integrating available data to provide estimates of the disease burden in this
49 population across the EU. Importantly, for a condition which was considered in the past to
50 be primarily a disease of young children, the average annual hospitalisation estimate in
51 adults was lower but of a similar magnitude to the estimate in young children aged 0-4
52 years: 158 229 (95%CI: 140 865–175 592) versus 245 244 (95%CI: 224 688 –265 799).

53 Keywords

54 Respiratory syncytial virus, adults, hospitalisation, European Union, burden

- 55
- 56 57
- 58
- 59

60 Introduction

61	Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections (ARI) in both
62	infants and older adults. In adult populations with RSV infections, lower respiratory tract
63	infection is common and can result in respiratory failure or death [1, 2]. RSV is a common
64	cause of hospitalisation for older adults especially in the winter months and the commonly
65	associated diagnoses include pneumonia and exacerbations of chronic conditions such as
66	chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), and asthma
67	[3-7]. Severe respiratory illnesses resulting from RSV infections with complications that
68	could be compared to those caused by seasonal influenza, often among influenza-
69	immunised populations, have been reported in hospitalised adults [2]. The mean length of
70	stay among RSV-associated hospitalisations as compared to influenza is longer among adults
71	(6.0 days vs 3.6 days) [8], and an even longer median length of stay of 9 days (6-25 days) has
72	been reported in adults hospitalised with RSV [9].
73	A high burden of RSV hospitalisations among adults, notably older adults and persons with
74	chronic conditions including transplantation, COPD, and CHF has been reported [10, 11].
75	Previous studies have reported varying estimates of the incidence of RSV infections in
76	hospitalised adults [5, 11, 12]. Estimating the incidence of RSV infection in hospitalised
77	adults remains challenging as there are no dedicated RSV surveillance systems, RSV is not
78	routinely screened for in patients with an ARI and only the more severe cases are commonly
79	diagnosed [13]. RSV-associated mortality among older adults is reportedly substantial and
80	comparable to influenza [14] with the majority of deaths occurring among persons aged \geq 60
81	years [8]. Global estimates indicate that the RSV-associated hospital admission rate and in-

82 hospital case fatality rate (hCFR) are higher among persons aged ≥65 years compared to

those aged 50-64 years [12]. Older adults may be more susceptible to viral and bacterial

84	diseases and complications including RSV-associated hospitalisations partly due to
85	immunosenescence [15] and the number of comorbidities that exist in this population [16].
86	It is recognised that RSV infections are common in older adults in high-income countries [7,
87	17]. To effectively plan healthcare resource utilisation and adequately manage the RSV-
88	related healthcare needs of the older adult population across Europe, including prioritising
89	preventive care, it is important to understand the RSV disease burden in this population. In
90	this study, we aimed to estimate the numbers and incidence rates of RSV-associated
91	hospital admissions in 28 European Union (EU) countries including the UK and Norway by
92	using data from a previously published REspiratory Syncytial virus Consortium in EUrope
93	(RESCEU) study [18] and a literature review.

94

Methods 95

We used a two-stage approach to estimate RSV-associated hospitalisations in adults across 96 97 the countries in the EU.

Stage 1 input data 98

99 In Stage 1, we gathered and used modelling inputs from the previously published RESCEU

- 100 project estimating nationally RSV-associated average annual hospitalisations and
- 101 hospitalisation rates for adults in Denmark, England, Finland, Norway, Netherlands, and
- Scotland from 2006 to 2017 [18]. These studies used time-series regression methods to 102
- estimate the RSV-associated numbers and rates of hospitalisation. 103

104 RSV hospital admission definition in RESCEU studies

105	In Stage 1, the previous RESCEU studies identified all respiratory hospital admissions using
106	ICD-10 codes at any point during an admission. The studies extracted all hospital admissions
107	with any mention of respiratory tract infection (RTI), RTI admissions with any mention of
108	pathogen-specific diagnosis code (pathogen-coded admissions) and RTI admissions with an
109	RSV diagnosis code (RSV-coded admissions) [18].
110	Scoping literature review
111	In addition, to complement RESCEU data, we conducted a scoping literature review in
112	November 2021 to identify estimates that used the same methodology in the RESCEU
113	studies. We searched Medline and Embase electronic databases using pre-defined terms to
114	identify original articles on RSV-associated hospitalisations (Supplementary File 1). The
115	search broadly focused on national estimates published in European countries between
116	2000 and 2021. Our search did not apply any language restrictions. Two independent
117	reviewers (ROY and MDR) conducted title and abstract screening, full-text screening and
118	data extraction. We followed the Preferred Reporting Items for Systematic Reviews and
119	Meta-Analyses (PRISMA) guidelines [19]. The diagnosis codes used to identify respiratory
120	diagnosis groups of the data sources that provided Stage 1 estimates are presented in Table
121	1.

122 Stage 2 statistical modelling

In Stage 2, we extracted the data from the six national RESCEU estimates to create the input
data. We extrapolated the input data to the EU using two different modelling approaches
the nearest-neighbour matching and multiple imputations, and two sets of 10 indicators
(Supplementary File 2) [20]. This resulted in four distributions of plausible values for each

127	country. Next, a hierarchical linear model was used to estimate a rate and confidence
128	interval for each country. These approaches generated four sets of estimates, with
129	confidence intervals and the averages of these estimates and the confidence intervals were
130	reported. We estimated the average number of RSV-associated hospitalisations and the
131	annual hospitalisation rates (per 1 000 adult population) by age group in the EU including
132	the UK and Norway. The outputs of the two modelling approaches for the EU are presented
133	in Supplementary Files 3-10.

134 Results

135 Scoping literature review

136 Of 1 392 citations assessed, five were identified to be eligible for inclusion in the analysis.

137 Two of the eligible studies provided estimates only for infants and data from these studies

138 were not included in this analysis. We found three eligible studies providing new estimates

139 for England [21-23], but because there were recent RESCEU estimates for England, the new

140 estimates found from the literature were not included as input data for Stage 2. The search

141 records of RSV-associated hospitalisation estimates are outlined in a PRISMA flowchart

142 (Figure 1).

143 Stage 2 estimates

144 Number of RSV-associated hospital admissions in 28 EU countries

Extrapolating the data from five EU countries and Norway to 28 EU countries (including the
UK), we estimate that on average 158 229 (95% Confidence Interval (CI): 140 865 – 175 592)
RSV-associated hospitalisations occurred annually among adults aged 18 years and older
(Table 2). The highest average annual number of RSV-associated hospital admissions among
adults aged 18-64 years: 2 896 (95% CI: 2 039 – 3 752), and ≥85 years: 6 002 (95% CI: 4 028 –

150	7 976) were estimated to occur in the UK whilst the highest average annual RSV-associated
151	number of hospital admissions for adults aged 65-74 years: 5 387 (95% CI: 3 885 – 6 889)
152	and 75-84 years: 13 843 (95% CI: 11 923 – 15 764) was estimated to occur in Germany
153	(Table 2). The lowest average annual RSV-associated number of hospital admissions in all
154	age groups occurs in Malta (Table 2). Of the overall RSV-associated hospital admissions, 145
155	102 (95%CI: 129 961- 160 242) occurred among adults older than 65 years per year. Among
156	adults aged 75-84 years, we estimate an average annual RSV-associated hospital admission
157	of 74 519 (95% CI: 69 923 – 79 115) at a rate of 2.24 (95% CI: 2.10-2.38) per 1 000 adults per
158	year (Table 3). The highest proportion of RSV-associated hospitalisations (47%) occurred in
159	this age group in the EU as well as in all countries compared to other age groups (Table 4). In
160	the 28 EU countries, 91.7% of all adult RSV-associated hospital admissions occurred in adults
161	older than 65 years (Table 4).
162	Importantly, the two model outputs did not differ significantly between the nearest-
163	neighbour matching and multiple imputation approaches using the two indicator sets. The
164	model only slightly differed by age group and the multiple imputation model estimates were
165	slightly higher than the nearest-neighbour matching models.
166	Rate of RSV-associated hospital admissions per age group and across 28 EU countries
167	The average annual RSV-associated hospital admission rates and numbers varied across the
168	EU. The estimated rate of hospitalisation was higher for adults ≥85 years (2.99, 95% CI: 2.56-
169	3.42 per 1 000) with an average number of hospital admission of 37 904 (95%CI: 32 444 – 43

170 363) per year. Persons aged 18-64 years had the lowest hospitalisation rate of 0.04 (95% CI:

171 0.03-0.05 per 1 000 per year) and average annual hospitalisation of 13 127 (95% CI: 10 904 –

172 15 350).

173	The highest hospital admission rate per 1 000 adults aged 18-64 years [0.07 (95% CI: 0.06 -
174	0.09)] was estimated in Ireland; the highest rates per 1 000 adults aged 65-74 years [1.37
175	(95% CI: 1.18 - 1.57)], 75-84 years [2.59 (95% CI: 2.29 - 2.88)] and ≥85 years [4.45 (95% CI:
176	3.61 - 5.28)] were estimated for Norway, Bulgaria and Romania respectively. The lowest
177	hospital admission rates per 1 000 adults aged 18-64 years [0.01 (95% CI:00 - 0.02)], 65-74
178	years [0.09 (95% CI:09 - 0.27)] and ≥85 years [1.12 (95% CI: 0.28 - 1.96)] were estimated in
179	Finland, whilst the lowest hospital admission rate in adults aged 75-84 years [1.53 (95% CI:
180	1.23 - 1.83) per 1 000] was estimated in the Netherlands (Table 3).

181

182 Discussion

183 RSV infection among older adults, especially those with underlying health conditions, is an 184 important cause of acute respiratory infections that can lead to hospitalisation. A previous 185 multi-site RSV burden cohort study conducted among healthy older adults and adults with 186 comorbidities in three European countries showed that RSV burden in both healthy older 187 adults and adults with comorbidities is substantial and comparable to influenza [24].

These estimates of RSV-associated hospitalisations in older adults are the first analysis 188 integrating available data in six European countries to provide empirical evidence of the 189 190 disease burden in this population across the EU. Our estimates show that RSV causes a high annual number of hospital admissions in adults across the EU (roughly 160 000 per year) 191 192 with about 92% of cases occurring in adults aged 65 years and older. The highest annual count of RSV-associated hospitalisations occurred among adults aged 75-84 years and the 193 highest rate of RSV-associated hospital admissions occurred among adults over 85 years. It 194 is important to note that for a condition which was considered in the past to be primarily a 195

196	disease of young children, the average RSV-associated hospitalisation estimate in adults was
197	lower, but of a similar magnitude to that in children aged 0-4 years: 158 229 (95%CI: 140
198	865 – 175 592) versus 245 244 (95%CI: 224 688 – 265 799) hospitalisations per year [25].
199	Indeed, taking the estimates for children aged 0-4 years into account; we estimate that 39%
200	(145 604 out of 371 299) of the annual number of RSV-associated hospitalisations in the EU
201	occurred in persons aged 65 years and older. With the changing demographics across
202	Europe where elderly populations are increasing in size and considering the fact that RSV
203	hospitalisation in adults can lead to acute functional decline and reduced quality of life [26],
204	there is a need to get better data and estimates of the true burden of RSV in this age group.
205	Our estimates, based on the available data, suggest a high burden of RSV in terms of
206	hospital admissions in adult populations. Several studies have previously reported the
207	burden and severity of clinical outcomes of RSV among adults in different settings [7, 9, 10,
208	27-30]. For instance, in previous studies, the prevalence of RSV has been reported to be two
209	times higher in patients aged over 75 years compared to those aged below 60 years [31].
210	Sundaram et al. report that RSV is a major cause of acute respiratory infection in adults aged
211	over 50 years and RSV infection is more frequently associated with adults aged 65-79 years
212	when compared to those aged 50-64 years [32]. In a community cohort of adults aged 50
213	years and over, the incidence of medically attended RSV infection was found to increase
214	with age and the highest incidence occurred among persons aged over 70 years [33]. Our
215	estimates of RSV-associated hospitalisation rates are consistent with the most recent
216	pooled estimates based on prospective surveillance and modelling from the USA which
217	report annual rates of RSV-associated hospitalisation of 178 (152-204) per 100 000 adults
218	aged ≥65 years [34]. Among adults aged ≥65 years in the US, about 159 000 RSV-associated
219	hospitalisations are estimated to occur each year which is comparable to our estimates of

220 over 145 000 hospitalisations occurring in the same age group across the EU [34]. We have 221 focused on RSV-associated hospital admission in older adults which is considered more severe, expensive and has quality of life implications [35], but recognise that there is also a 222 significant amount of RSV disease burden in the outpatient setting [36]. 223 224 Our study had several important limitations. The national estimates used for the 225 extrapolations were generated mainly from Northern and Western European countries. Additional national estimates from Southern and Eastern Europe would yield more 226 227 representative and reliable estimates for the EU. The two sets of ten indicators used to produce the extrapolations were selected based on their availability in all the countries 228 229 included and are not (always) specific to RSV. Future estimates generated with this 230 approach should attempt to use a more RSV-aligned set of indicators (e.g., indoor and outdoor pollution, geographical and ecological factors, etc.). The estimates used for Stage 1 231 were based on the overall number of hospitalisations with respiratory infections along with 232 233 weekly test positives from laboratory data. The number of admissions and positive tests 234 differed between the included countries, and as such, the estimates are still affected by 235 country- or age-specific coding practices. Our estimates may differ from other studies using a similar approach because the Stage 1 results used depended on overall, non-age-specific 236 virology data and the regression models were built with seasonal trends and polynomials 237 [18]. It would be useful to provide estimates by year, as has been done for influenza-238 239 associated respiratory mortality for the EU [37], to assess temporal trends in RSV-associated 240 hospitalisations and to produce more recent estimates to better understand how the COVID-19 pandemic has influenced RSV activity and its burdens such as infections, 241 hospitalisations, and deaths. 242

There is also a lot of uncertainty due to low proportions of cases tested for RSV. These 243 uncertainties may be mitigated only by using the observed number of admissions with a 244 specific diagnosis or if laboratory confirmation of diagnosis (all cases tested), and lower 245 sensitivity of testing methods in this age group are improved by combining polymerase 246 247 chain reaction (PCR) and serology. With RSV, the reported burden of disease is broadly considered too low, a problem attributed to low levels of routine testing being used, and 248 imperfect reporting of hospitalisation ICD-10 codes [38, 39]. In addition, routine diagnostic 249 250 testing may not be appropriate for adults with RSV due to lower viral loads in adults compared to children [28, 40]. While the estimated burden of disease might be generally 251 more uncertain, the high proportion of RSV-associated hospital admissions is more likely to 252 reflect the overall healthcare burden and daily experiences of clinical professionals. The 253 difference may even be larger in the elderly as this group is more often hospitalised due to 254 255 other respiratory reasons than RSV and testing for RSV is probably done in only a limited 256 number of elderly patients.

We have based this work on regression model estimates [which are not so dependent on high levels of RSV testing] to increase the comparability of the Stage 1 estimates [41] and to limit the risk of underestimating the RSV disease burden in adults (as there is less testing in this age group)[13]. Considering that the review of the literature found no eligible recent studies, there is a need for more data from more countries to generate improved estimates with less uncertainty as the uncertainty intervals given here are falsely narrow and do not capture all sources of uncertainty.

The main strength of this work is that we have used national data from several countries in
a single agreed analysis framework to estimate the RSV-associated hospital admission

266	burden for the EU. Our estimates provide a key insight into the healthcare burden that may
267	be associated with RSV infection and can be used to inform healthcare planning, priority
268	setting and resource allocation. Our results are important for public health policy and
269	practice as these estimates may guide development of RSV surveillance systems, provide
270	baseline evidence for the introduction of future vaccines, and raise awareness to generate
271	more granular data. These data should therefore contribute to decision-making and policy
272	formulation to improve relevant prevention, diagnostics and healthcare service delivery for
273	this population.

Table 1. Diagnosis codes used to identify respiratory diagnosis groups of the data sources that provided Stage 1 estimates

Author, year	Country	Period of observation	Age groups	Outcome coding
Johannesen etal., 2022	Denmark	2010-2017		
Johannesen et al., 2022	England	2007-2017	0-2m, 3-5m, 6-	
Johannesen et al., 2022	Finland	2006-2016	11m, 1-2y, 3-4y, 5-17y,18-64y, 65-74y, 75-84y,	ICD-10: Acute upper respiratory tract infection (URTI) (J00, J02-06); Pneumonia & influenza (J09-18); Bronchiolitis and bronchitis (J20-21, J40);
Johannesen et al., 2022	Netherlands	2013-2017		Unspecified LRTI (J22)
Johannesen et al., 2022	Norway	2008-2017		
Johannesen et al., 2022	Scotland	2010-2016		

Country	18-64 years	65-74 years	75-84 years	≥85 years	≥65 years
EU 28*	13127 (10904, 15350)	32679 (27594, 37764)	74519 (69923, 79115)	37904 (32444, 43363)	145102 (129961, 160242)
Austria	202 (132, 272)	587 (433, 740)	1155 (1002, 1309)	614 (434, 795)	2356 (1869, 2844)
Belgium	332 (244, 420)	638 (456, 820)	1608 (1396, 1820)	1094 (852 <i>,</i> 1335)	3340 (2704, 3975)
Bulgaria	207 (149, 265)	494 (346, 641)	1253 (1110, 1396)	412 (308, 516)	2159 (1764, 2553)
Croatia	94 (60, 127)	222 (146, 296)	737 (648, 825)	213 (151, 275)	1172 (945, 1396)
Cyprus	34 (27, 41)	55 (42 <i>,</i> 68)	100 (88, 112)	46 (36, 56)	201 (166, 236)
Czech Republic	305 (220, 391)	736 (530, 941)	1252 (1091, 1413)	526 (374, 678)	2514 (1995, 3032)
Denmark	138 (94, 181)	396 (284, 509)	675 (584, 767)	188 (89, 287)	1259 (957, 1563)
Estonia	35 (24, 45)	62 (40, 85)	207 (180, 234)	84 (59, 108)	353 (279, 427)
Finland	26 (-16, 68)	55 (-56, 166)	795 (693, 896)	150 (38, 262)	1000 (675, 1324)
France	1637 (1153, 2121)	4244 (3172, 5316)	7662 (6471, 8854)	5901 (4258, 7543)	17807 (13901, 21713)
Germany	1393 (746, 2040)	5387 (3885, 6889)	13843 (11923, 15764)	4514 (2713, 6314)	23744 (18521, 28967)
Greece	249 (164, 334)	526 (331, 721)	2133 (1876, 2390)	967 (706, 1227)	3626 (2913 <i>,</i> 4338)
Hungary	262 (181, 342)	679 (498 <i>,</i> 859)	1332 (1163, 1500)	512 (360, 664)	2523 (2021, 3023)
Ireland	214 (178, 251)	322 (260, 385)	459 (402, 514)	224 (169, 279)	1005 (831, 1178)
Italy	1347 (876, 1817)	3603 (2444, 4762)	10531 (9126, 11936)	4419 (2818, 6021)	18553 (14388, 22719)
Latvia	43 (27, 59)	108 (72 <i>,</i> 144)	341 (299, 383)	135 (100, 170)	584 (471, 697)
Lithuania	56 (33, 80)	159 (109, 208)	482 (421, 542)	231 (177, 286)	872 (707, 1036)
Luxembourg	21 (16, 25)	43 (35, 50)	59 (51, 67)	39 (30, 47)	141 (116, 164)
Malta	12 (9, 16)	37 (29, 46)	58 (50 <i>,</i> 65)	20 (13, 26)	115 (92 <i>,</i> 137)
Netherlands	429 (296, 561)	1000 (689, 1311)	1427 (1150, 1704)	1040 (751, 1328)	3467 (2590 <i>,</i> 4343)
Norway	158 (117, 199)	651 (558, 744)	515 (441, 589)	393 (295, 491)	1559 (1294, 1824)
Poland	970 (645, 1295)	2254 (1685, 2823)	4445 (3851, 5039)	2246 (1690, 2802)	8945 (7226, 10664)
Portugal	252 (170, 333)	543 (352, 734)	1609 (1383, 1835)	943 (712, 1173)	3095 (2447, 3742)
Romania	738 (576, 900)	1422 (1100, 1745)	2759 (2393, 3125)	1430 (1162, 1699)	5611 (4655, 6569)
Slovakia	145 (98, 191)	386 (305, 466)	570 (501, 639)	249 (189, 308)	1205 (995, 1413)
Slovenia	44 (27, 61)	85 (51, 120)	311 (272, 350)	100 (64, 137)	496 (387, 607)

Average annual number of hospitalisations (95% confidence interval) per age group

Table 2: Estimated average annual RSV-associated hospitalisations by age groups in 28 EU countries (including the UK) and Norway

Spain	1031 (657, 1405)	2509 (1742, 3275)	5409 (4530, 6288)	3217 (2133, 4301)	11135 (8405 <i>,</i> 13864)
Sweden	285 (211, 360)	681 (488 <i>,</i> 876)	1220 (1048, 1392)	660 (445 <i>,</i> 875)	2561 (1981, 3143)
United Kingdom	2896 (2039, 3752)	4846 (2860, 6832)	8625 (7034, 10216)	6002 (4028, 7976)	19473 (13922, 25024)

284 *Includes United Kingdom and excludes Norway

Table 3: Estimated rates of annual RSV-associated hospitalisations by age groups per 1 000

adults in 28 EU countries (including the UK) and Norway

	Rate of hospitalisation per 1 000 adults (95% confidence interval) per age				
Country	18-64 years	65-74 years	oup 75-84 years	≥85 years	
EU 28*	0.04 (0.03, 0.05)	0.66 (0.55, 0.76)	2.24 (2.10, 2.38)	2.99 (2.56, 3.42)	
Austria	0.04 (0.02, 0.05)	0.69 (0.51, 0.87)	2.23 (1.94, 2.53)	2.86 (2.02, 3.70)	
Belgium	0.05 (0.04, 0.06)	0.62 (0.45, 0.80)	2.23 (1.94, 2.53)	3.79 (2.95, 4.62)	
Bulgaria	0.05 (0.03, 0.06)	0.59 (0.42, 0.77)	2.59 (2.29, 2.88)	3.30 (2.46, 4.14)	
Croatia	0.04 (0.02, 0.05)	0.53 (0.35, 0.70)	2.46 (2.16, 2.75)	2.87 (2.03, 3.70)	
Cyprus	0.06 (0.05, 0.07)	0.76 (0.58, 0.93)	2.53 (2.23, 2.82)	3.94 (3.10, 4.77)	
Czech Republic	0.04 (0.03, 0.06)	0.64 (0.46, 0.82)	2.30 (2.00, 2.59)	2.89 (2.05, 3.72)	
Denmark	0.04 (0.03, 0.05)	0.63 (0.45, 0.81)	2.19 (1.89, 2.49)	1.60 (0.76, 2.44)	
Estonia	0.04 (0.03, 0.05)	0.49 (0.31, 0.67)	2.28 (1.99, 2.58)	2.87 (2.03, 3.71)	
Finland	0.01 (0.00, 0.02)	0.09 (09, 0.27)	2.32 (2.03, 2.62)	1.12 (0.28, 1.96)	
France	0.04 (0.03, 0.06)	0.70 (0.53, 0.88)	1.90 (1.60, 2.19)	3.01 (2.18, 3.85)	
Germany	0.03 (0.01, 0.04)	0.64 (0.46, 0.82)	2.13 (1.83, 2.42)	2.10 (1.26, 2.94)	
Greece	0.04 (0.02, 0.05)	0.48 (0.30, 0.66)	2.45 (2.15, 2.74)	3.10 (2.27, 3.94)	
Hungary	0.04 (0.03, 0.05)	0.67 (0.49, 0.85)	2.33 (2.04, 2.63)	2.82 (1.99, 3.66)	
Ireland	0.07 (0.06, 0.09)	0.92 (0.74, 1.10)	2.42 (2.13, 2.72)	3.37 (2.54, 4.21)	
Italy	0.04 (0.02, 0.05)	0.55 (0.38, 0.73)	2.21 (1.92, 2.51)	2.31 (1.47, 3.14)	
Latvia	0.03 (0.02, 0.05)	0.54 (0.36, 0.71)	2.40 (2.11, 2.70)	3.22 (2.38, 4.05)	
Lithuania	0.03 (0.02, 0.04)	0.57 (0.39, 0.75)	2.35 (2.05, 2.64)	3.58 (2.75, 4.42)	
Luxembourg	0.06 (0.04, 0.07)	1.02 (0.84, 1.20)	2.14 (1.84, 2.44)	3.82 (2.99, 4.66)	
Malta	0.04 (0.03, 0.06)	0.78 (0.60, 0.96)	2.35 (2.05, 2.65)	2.64 (1.80, 3.49)	
Netherlands	0.04 (0.03, 0.05)	0.58 (0.40, 0.76)	1.53 (1.23, 1.83)	3.02 (2.18, 3.86)	
Norway	0.05 (0.04, 0.06)	1.37 (1.18, 1.57)	2.10 (1.80, 2.41)	3.42 (2.56, 4.27)	
Poland	0.04 (0.03, 0.05)	0.70 (0.53, 0.88)	2.21 (1.91, 2.51)	3.38 (2.54, 4.21)	
Portugal	0.04 (0.03, 0.05)	0.51 (0.33, 0.68)	2.10 (1.80, 2.40)	3.43 (2.59, 4.26)	
Romania	0.06 (0.05, 0.07)	0.78 (0.61, 0.96)	2.22 (1.93, 2.52)	4.45 (3.61, 5.28)	
Slovakia	0.04 (0.03, 0.05)	0.85 (0.68, 1.03)	2.43 (2.13, 2.72)	3.48 (2.65, 4.32)	
Slovenia	0.03 (0.02, 0.05)	0.44 (0.26, 0.62)	2.37 (2.07, 2.66)	2.32 (1.48, 3.15)	
Spain	0.03 (0.02, 0.05)	0.58 (0.40, 0.76)	1.82 (1.52, 2.11)	2.48 (1.65, 3.32)	
Sweden	0.05 (0.04, 0.06)	0.63 (0.45, 0.81)	2.11 (1.81, 2.41)	2.58 (1.74, 3.42)	
United Kingdom	0.07 (0.05, 0.09)	0.77 (0.46, 1.09)	2.31 (1.89, 2.74)	3.95 (2.65, 5.25)	

*Includes United Kingdom and excludes Norway

Table 4: Proportion of overall RSV-associated hospitalisations occurring in adults aged 18-64

295	years, 65-74 years, 75-84 years and ≥85 years in the EU and in each country
-----	---

Country	10 64	CE 74	75.04	NOF	
Country	18-64 years	65-74 years	75-84 years	≥85 years	≥65 years
EU 28*	8.3	20.7	47.1	24.0	91.7
Austria	7.9	22.9	45.2	24.0	92.1
Belgium	9.0	17.4	43.8	29.8	91.0
Bulgaria	8.7	20.9	53.0	17.4	91.3
Croatia	7.4	17.5	58.2	16.8	92.6
Cyprus	14.5	23.4	42.6	19.6	85.5
Czech Republic	10.8	26.1	44.4	18.7	89.2
Denmark	9.9	28.3	48.3	13.5	90.1
Estonia	9.0	16.0	53.4	21.6	91.0
Finland	2.5	5.4	77.5	14.6	97.5
France	8.4	21.8	39.4	30.3	91.6
Germany	5.5	21.4	55.1	18.0	94.5
Greece	6.4	13.6	55.0	25.0	93.6
Hungary	9.4	24.4	47.8	18.4	90.6
Ireland	17.6	26.4	37.7	18.4	82.4
Italy	6.8	18.1	52.9	22.2	93.2
Latvia	6.9	17.2	54.4	21.5	93.1
Lithuania	6.0	17.1	51.9	24.9	94.0
Luxembourg	13.0	26.5	36.4	24.1	87.0
Malta	9.4	29.1	45.7	15.7	90.6
Netherlands	11.0	25.7	36.6	26.7	89.0
Norway	9.2	37.9	30.0	22.9	90.8
Poland	9.8	22.7	44.8	22.7	90.2
Portugal	7.5	16.2	48.1	28.2	92.5
Romania	11.6	22.4	43.5	22.5	88.4
Slovakia	10.7	28.6	42.2	18.4	89.3
Slovenia	8.1	15.7	57.6	18.5	91.9
Spain	8.5	20.6	44.5	26.4	91.5
Sweden	10.0	23.9	42.9	23.2	90.0
United Kingdom	12.9	21.7	38.6	26.8	87.1

296

297 *Includes United Kingdom and excludes Norway

298





Figure 1: PRISMA flowchart outlining the search records of RSV-associated hospitalisation estimates in **European countries**


300

- Figure 1: PRISMA flowchart outlining the search records of RSV-associated hospitalisation 301
- estimates in European countries. 302

303



305



307 Norway. A: RSV-associated hospitalisation rates per 1 000 in adults aged 18-64 years. B:

308 RSV-associated hospitalisation rates per 1 000 in adults aged 65-74 years. C: RSV-associated

hospitalisation rates per 1 000 in adults aged 75-84 years. D: RSV-associated hospitalisation 309

rates per 1 000 in adults aged \geq 85 years. 310

311

313 Footnote Page

- 314 The RESCEU investigators are as follows:
- 315 Harish NAIR (University of Edinburgh), Harry CAMPBELL (University of Edinburgh), Philippe Beutels
- 316 (Universiteit Antwerpen), Louis Bont (University Medical Center Utrecht), Andrew Pollard (University
- of Oxford), Peter Openshaw (Imperial College London), Federico Martinon-Torres (Servicio Galego de
- 318 Saude), Terho Heikkinen (University of Turku and Turku University Hospital), Adam Meijer (National
- 319 Institute for Public Health and the Environment), Thea K. Fischer (Statens Serum Institut), Maarten
- 320 van den Berge (University of Groningen), Carlo Giaquinto (PENTA Foundation), Michael Abram
- 321 (AstraZeneca), Kena Swanson (Pfizer), Bishoy Rizkalla (GlaxoSmithKline), Charlotte Vernhes (Sanofi
- 322 Pasteur), Scott Gallichan (Sanofi Pasteur), Jeroen Aerssens (Janssen), Veena Kumar (Novavax), Eva
- 323 Molero (Team-It Research).

324 Financial support

- 325 This work is part of RESCEU. RESCEU has received funding from the Innovative Medicines Initiative 2
- 326 Joint Undertaking under grant agreement No 116019. This Joint Undertaking receives support from
- 327 the European Union's Horizon 2020 research and innovation programme and EFPIA. This
- 328 publication only reflects the author's view and the JU is not responsible for any use that may be
- 329 made of the information it contains herein.

330 Disclaimer

Data from the Norwegian Patient Registry have been used in this publication. The interpretation and
reporting of these data are the sole responsibility of the authors, and no endorsement by the
Norwegian Patient Registry is intended nor should be inferred. This work reflects only the author's
views and opinions. The EC is not responsible for any use that may be made of the information it
contains.

336 Potential conflict of interests

337 HC reports grants, personal fees, and nonfinancial support from World Health Organization. Grants

and personal fees from Sanofi Pasteur. Grants from Bill and Melinda Gates Foundation. All payments

- 339 were made via the University of Edinburgh. HC is a shareholder in the Journal of Global Health
- 340 Ltd. JP declares that Nivel has received unrestricted research grants regarding the epidemiology of
- 341 RSV from Sanofi Pasteur and IMI in the past 12 months. All other authors report no potential
- 342 conflicts.
- 343

344 Reference

Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under recognized problem. Drugs Aging. 2015;32(4):261-9.

Atamna A, Babich T, Froimovici D, Yahav D, Sorek N, Ben-Zvi H, et al. Morbidity and mortality
 of respiratory syncytial virus infection in hospitalized adults: Comparison with seasonal influenza. Int
 J Infect Dis. 2021;103:489-93.

Falsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, et al. Respiratory syncytial
 virus and other respiratory viral infections in older adults with moderate to severe influenza-like
 illness. J Infect Dis. 2014;209(12):1873-81.

Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P, et al. Respiratory syncytial virus
 infection-associated hospitalization in adults: a retrospective cohort study. BMC Infectious Diseases.
 2014;14(665):1471-2334.

Widmer K, Griffin MR, Zhu Y, Williams JV, Talbot HK. Respiratory syncytial virus- and human
 metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other
 Respir Viruses. 2014;8(3):347-52.

Alexa Naorat S, Chittaganpitch M, Thamthitiwat S, Henchaichon S, Sawatwong P, Srisaengchai P, et
al. Hospitalizations for acute lower respiratory tract infection due to respiratory syncytial virus in
Thailand, 2008-2011. J Infect Dis. 2013;208 Suppl 3:S238-45.

362 7. Lee N, Lui GC, Wong KT, Li TC, Tse EC, Chan JY, et al. High morbidity and mortality in adults
 363 hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57(8):1069-77.

Pastula ST, Hackett J, Coalson J, Jiang X, Villafana T, Ambrose C, et al. Hospitalizations for
 Respiratory Syncytial Virus Among Adults in the United States, 1997-2012. Open Forum Infect Dis.
 2017;4(1):ofw270.

367 9. Loubet P, Lenzi N, Valette M, Foulongne V, Krivine A, Houhou N, et al. Clinical characteristics
368 and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like
369 illness in France. Clin Microbiol Infect. 2017;23(4):253-9.

Branche AR, Saiman L, Walsh EE, Falsey AR, Sieling WD, Greendyke W, et al. Incidence of
Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020. Clin Infect Dis.
2022;74(6):1004-11.

Tin Tin Htar M, Yerramalla MS, Moisi JC, Swerdlow DL. The burden of respiratory syncytial
virus in adults: a systematic review and meta-analysis. Epidemiol Infect. 2020;148:e48.

375 12. Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global Disease Burden

- 376 Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in
- 2015: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):S577-S83.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.09.23287042; this version posted March 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

378 13. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al. Under-379 ascertainment of Respiratory Syncytial Virus infection in adults due to diagnostic testing limitations: 380 A systematic literature review and meta-analysis. J Infect Dis. 2023. 381 14. Hansen CL, Chaves SS, Demont C, Viboud C. Mortality Associated With Influenza and 382 Respiratory Syncytial Virus in the US, 1999-2018. JAMA Netw Open. 2022;5(2):e220527. 383 15. Allen JC, Toapanta FR, Chen W, Tennant SM. Understanding immunosenescence and its 384 impact on vaccination of older adults. Vaccine. 2020;38(52):8264-72. 385 Yarnall AJ, Sayer AA, Clegg A, Rockwood K, Parker S, Hindle JV. New horizons in 16. 386 multimorbidity in older adults. Age Ageing. 2017;46(6):882-8. 387 Falsey AR. Editorial commentary: respiratory syncytial virus: a global pathogen in an aging 17. 388 world. Clin Infect Dis. 2013;57(8):1078-80. 389 Johannesen CK, van Wijhe M, Tong S, Fernandez LV, Heikkinen T, van Boven M, et al. Age-18. 390 Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: 391 A Time Series Analysis. J Infect Dis. 2022;226:S29-S37. 392 19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 393 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 394 20. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global 395 mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. 396 PLoS Med. 2013;10(11):e1001558. 397 Mangtani P, Hajat S, Kovats S, Wilkinson P, Armstrong B. The Association of Respiratory 21. 398 Syncytial Virus Infection and Influenza with Emergency Admissions for Respiratory Disease in 399 London: An Analysis of Routine Surveillance Data. Clinical Infectious Disease. 2006;42(5):640-6. 400 22. Muller-Pebody B, Crowcroft NS, Zambon MC, Edmunds WJ. Modelling hospital admissions 401 for lower respiratory tract infections in the elderly in England. Epidemiol Infect. 2006;134(6):1150-7. 402 23. Sharp A, Minaji M, Panagiotopoulos N, Reeves R, Charlett A, Pebody R. Estimating the 403 burden of adult hospital admissions due to RSV and other respiratory pathogens in England. 404 Influenza Other Respir Viruses. 2022;16(1):125-31. 405 24. Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, et al. Burden of 406 respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an 407 international prospective cohort study. Eur Respir J. 2021;57(4). 408 25. Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, Klint Johannesen C, Vazquez Fernandez L, 409 Teirlinck A, et al. Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated 410 hospitalisations in children under 5 years of age. A systematic review and modelling study. medRxiv 411 [Preprint]. 2023. 412 26. Branche AR, Saiman L, Walsh EE, Falsey AR, Jia H, Barrett A, et al. Change in functional status 413 associated with respiratory syncytial virus infection in hospitalized older adults. Influenza Other 414 Respir Viruses. 2022;16(6):1151-60. 415 27. Boattini M, Almeida A, Christaki E, Marques TM, Tosatto V, Bianco G, et al. Severity of RSV 416 infection in Southern European elderly patients during two consecutive winter seasons (2017-2018). 417 J Med Virol. 2021;93(8):5152-7. Talbot HK, Belongia EA, Walsh EE, Schaffner W. Respiratory Syncytial Virus in Older Adults: A 418 28. 419 Hidden Annual Epidemic. Infectious Diseses in Clinical Practice. 2016;24(6):295-302. 420 Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling 29. 421 estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the 422 United Kingdom. BMC Infect Dis. 2015;15:443. 423 30. Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, et al. The 424 epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A 425 systematic review. PLoS One. 2017;12(8):e0182321. Bruyndonckx R, Coenen S, Butler C, Verheij T, Little P, Hens N, et al. Respiratory syncytial 426 31. 427 virus and influenza virus infection in adult primary care patients: Association of age with prevalence,

428 diagnostic features and illness course. Int J Infect Dis. 2020;95:384-90.

- 429 32. Sundaram ME, Meece JK, Sifakis F, Gasser RA, Jr., Belongia EA. Medically attended respiratory syncytial virus infections in adults aged >/= 50 years: clinical characteristics and 430 431 outcomes. Clin Infect Dis. 2014;58(3):342-9.
- 432 33. McClure DL, Kieke BA, Sundaram ME, Simpson MD, Meece JK, Sifakis F, et al. Seasonal 433 incidence of medically attended respiratory syncytial virus infection in a community cohort of adults 434 >/=50 years old. PLoS One. 2014;9(7):e102586.
- 435 McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of Medically 34. 436 Attended RSV Among US Adults: A Systematic Review and Meta-analysis. Open Forum Infect Dis.
- 437 2022;9(7):ofac300.
- 438 Rafferty E, Paulden M, Buchan SA, Robinson JL, Bettinger JA, Kumar M, et al. Evaluating the 35. 439 Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups. 440 Pharmacoeconomics. 2022;40(6):633-45.
- 441 Belongia EA, King JP, Kieke BA, Pluta J, Al-Hilli A, Meece JK, et al. Clinical Features, Severity, 36. 442 and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults >/=60 443 Years Old. Open Forum Infect Dis. 2018;5(12):ofy316.
- 444 Paget J, Danielle Iuliano A, Taylor RJ, Simonsen L, Viboud C, Spreeuwenberg P, et al. 37.
- 445 Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR 446 project. Vaccine. 2022;40(9):1361-9.
- 38. 447 Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 448 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630-449 7.
- 450 39. Hamilton MA, Calzavara A, Emerson SD, Djebli M, Sundaram ME, Chan AK, et al. Validating 451 International Classification of Disease 10th Revision algorithms for identifying influenza and
- 452 respiratory syncytial virus hospitalizations. PLoS One. 2021;16(1):e0244746. 453 40. Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy
- 454 to old age. Thorax. 2019;74(10):986-93.
- 455 Paget J, Staadegaard L, Wang X, Li Y, van Pomeren T, van Summeren J, et al. Global and 41. 456 national influenza-associated hospitalisation rates: Estimates for 40 countries and administrative
- 457 regions. J Glob Health. 2023;13:04003.